Hiroaki Ishida1, Go Ogura2, Saeko Uehara1, Shinya Takiguchi1, Yousuke Nakagawa3, Naoto Hamano3, Masahiro Koizumi3, Takehiko Wada3, Masafumi Fukagawa3, Michio Nakamura4. 1. Department of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. 2. Department of Pathology, Tokai University School of Medicine, Shimokasuya, Isehara, Japan. 3. Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Shimokasuya, Isehara, Japan. 4. Department of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. mnakamura@tokai-u.jp.
Abstract
BACKGROUND: To improve the long-term outcomes following renal transplantation, prevention of renal-allograft interstitial fibrosis (IF), mainly due to calcineurin inhibitors, is an important therapeutic target. Everolimus (EVR) was reported to have antifibrotic effects. We aimed to investigate the safety, efficacy, and IF of our modified immunosuppressive regimen, which includes early introduction of EVR and reduced-exposure tacrolimus (Tac) (EVR group), and compare it with the standard-exposure tacrolimus-based regimen (Tac group) in de novo living-donor renal recipients. METHODS: In this retrospective, single-center cohort study, we compared the 2-year clinical courses between the two groups according to intention to treat. Additionally, in patients in whom biopsies were obtained at 1 h, 3 months, and 12 months post-transplant, we compared IF between the groups using imaging analysis. RESULTS: Overall, 47 patients were included (EVR group, n = 22; Tac group, n = 25). There were no significant differences in renal function and incidences of rejection and viral infections between the groups at the 2-year post-transplant follow-up. However, pathologic imaging analysis (n = 34) revealed chronological progression of IF in the Tac group during the first year post-transplant and no changes in the EVR group (fibrosis rate at 3 months: 20.8 vs. 13.6%, p < 0.001; at 12 months: 24.7 vs. 14.7%, p < 0.001, respectively). CONCLUSION: Our modified immunosuppressive regimen may have an antifibrotic effect on transplanted kidneys without loss of safety and efficacy.
BACKGROUND: To improve the long-term outcomes following renal transplantation, prevention of renal-allograft interstitial fibrosis (IF), mainly due to calcineurin inhibitors, is an important therapeutic target. Everolimus (EVR) was reported to have antifibrotic effects. We aimed to investigate the safety, efficacy, and IF of our modified immunosuppressive regimen, which includes early introduction of EVR and reduced-exposure tacrolimus (Tac) (EVR group), and compare it with the standard-exposure tacrolimus-based regimen (Tac group) in de novo living-donor renal recipients. METHODS: In this retrospective, single-center cohort study, we compared the 2-year clinical courses between the two groups according to intention to treat. Additionally, in patients in whom biopsies were obtained at 1 h, 3 months, and 12 months post-transplant, we compared IF between the groups using imaging analysis. RESULTS: Overall, 47 patients were included (EVR group, n = 22; Tac group, n = 25). There were no significant differences in renal function and incidences of rejection and viral infections between the groups at the 2-year post-transplant follow-up. However, pathologic imaging analysis (n = 34) revealed chronological progression of IF in the Tac group during the first year post-transplant and no changes in the EVR group (fibrosis rate at 3 months: 20.8 vs. 13.6%, p < 0.001; at 12 months: 24.7 vs. 14.7%, p < 0.001, respectively). CONCLUSION: Our modified immunosuppressive regimen may have an antifibrotic effect on transplanted kidneys without loss of safety and efficacy.
Authors: H Tedesco Silva; D Cibrik; T Johnston; E Lackova; K Mange; C Panis; R Walker; Z Wang; G Zibari; Y S Kim Journal: Am J Transplant Date: 2010-04-28 Impact factor: 8.086
Authors: Robert M Langer; Ronald Hené; Stefan Vitko; Maarten Christiaans; Helio Tedesco-Silva; Kazimierz Ciechanowski; Elisabeth Cassuto; Lionel Rostaing; Mario Vilatoba; Uwe Machein; Bettina Ulbricht; Guido Junge; Gaohong Dong; Julio Pascual Journal: Transpl Int Date: 2012-03-26 Impact factor: 3.782
Authors: Regiane F Rivelli; Renato T Gonçalves; Maurilo Leite; Marcos André R Santos; Alvimar G Delgado; Lucio R Cardoso; Christina M Takiya Journal: Nephrology (Carlton) Date: 2015-03 Impact factor: 2.506
Authors: Klemens Budde; Thomas Becker; Wolfgang Arns; Claudia Sommerer; Petra Reinke; Ute Eisenberger; Stefan Kramer; Wolfgang Fischer; Harald Gschaidmeier; Frank Pietruck Journal: Lancet Date: 2011-02-19 Impact factor: 79.321
Authors: M Naesens; D R J Kuypers; K De Vusser; Y Vanrenterghem; P Evenepoel; K Claes; B Bammens; B Meijers; E Lerut Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086